TickerFacts.

Compare

Assembly Biosciences, Inc. vs Bicycle Therapeutics PLC vs Viridian Therapeutics, Inc. vs AbCellera Biologics Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearAssembly Biosciences, Inc.
ASMB		Bicycle Therapeutics PLC
BCYC		Viridian Therapeutics, Inc.
VRDN		AbCellera Biologics Inc.
ABCL
Year ended2025-12-312025-12-312025-12-312025-12-31
Revenue$72.30M$72.59M$70.85M$75.13M
Revenue growth (YoY)+153.5%+105.8%n/m+160.6%
Gross marginn/an/an/an/a
Operating margin-16.8%-340.4%-512.9%-289.0%
Net margin-8.5%-301.7%-483.6%-194.9%
Net income-$6.12M-$218.96M-$342.60M-$146.41M
EPS (Diluted)-$0.55-$3.16n/a-$0.49
Operating cash flow-$41.09M-$249.68M-$276.39M-$131.29M
Free cash flow-$41.16M-$252.03M-$276.89M-$174.07M
Cash & equivalents$58.45M$628.11Mn/a$128.51M
Total assets$257.59M$717.60M$899.42M$1.36B
Total liabilities$50.84M$107.62M$177.25M$390.05M
Shareholders' equity$206.75M$609.98M$722.17M$966.90M
Return on year-end equity-3.0%-35.9%-47.4%-15.1%
Shares outstanding15.86M69.37M101.83M300.60M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearAssembly Biosciences, Inc.Bicycle Therapeutics PLCViridian Therapeutics, Inc.AbCellera Biologics Inc.
Latest$72.30M
Ended 2025-12-31		$72.59M
Ended 2025-12-31		$70.85M
Ended 2025-12-31		$75.13M
Ended 2025-12-31
1 year earlier$28.52M
Ended 2024-12-31		$35.27M
Ended 2024-12-31		$302.0K
Ended 2024-12-31		$28.83M
Ended 2024-12-31
2 years earlier$7.16M
Ended 2023-12-31		$26.98M
Ended 2023-12-31		$314.0K
Ended 2023-12-31		$38.02M
Ended 2023-12-31
3 years earlier$0
Ended 2022-12-31		$14.46M
Ended 2022-12-31		$1.77M
Ended 2022-12-31		$485.42M
Ended 2022-12-31
4 years earlier$6.25M
Ended 2021-12-31		$11.70M
Ended 2021-12-31		$2.96M
Ended 2021-12-31		$375.20M
Ended 2021-12-31